Last reviewed · How we verify
NCT03777371
Anti-HIV False Positivity Rate in Pregnant Women; and Investigating the Factors Affecting This Situation
trial testing Anti HIV Seropositive Pregnant Women in HIV Seropositivity in 128 participants. Completed in 1 December 2018.
1 December 2018
Quick facts
| Lead sponsor | Kanuni Sultan Suleyman Training and Research Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 128 |
| Start date | 1 January 2014 |
| Primary completion | 1 December 2018 |
| Estimated completion | 1 December 2018 |
Drugs / interventions tested
- Anti HIV Seropositive Pregnant Women
Conditions studied
- HIV Seropositivity — all drugs for HIV Seropositivity →
- Acquired Immunodeficiency Syndrome — all drugs for Acquired Immunodeficiency Syndrome →
- Pregnancy, High Risk — all drugs for Pregnancy, High Risk →
Sponsor
Kanuni Sultan Suleyman Training and Research Hospital
Who can join
Eligibility, female only, with HIV Seropositivity or Acquired Immunodeficiency Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
HIV virus is an etiologic agent of ( AIDS ) immunodeficiency syndrome . It is known that the estimated rate of transfer from mother to baby is 25% to 45%, pregnancy rate is 5-10%, pregnancy rate is 15-20% and in lactation period is 5-10%. Risk factors; maternal viral load, breastfeeding, vaginal birth, and prematurity. Although there is a high rate of false positivity in prenatal screening in our country, one of the factors affecting this is the number of pregnancies.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03777371
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for HIV Seropositivity
Currently open trials in the same condition.
- NCT06799650 — Clinical Trial of Gammora® Plus Antiretroviral Treatment for HIV · Phase 2 · recruiting
- NCT05122026 — Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics · Phase 1, PHASE2 · active not recruiting
- NCT05118490 — Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Is · Phase 4 · active not recruiting
- NCT05723653 — Hybrid Type I Effectiveness-Implementation Trial of a Social Network Support Intervention · NA · recruiting
- NCT04832477 — Assessing the PrEP Care Cascade Among Black Men and Transwomen in the Southeastern US · NA · active not recruiting
Other Kanuni Sultan Suleyman Training and Research Hospital trials
Trials by the same sponsor.
- NCT07519551 — Serum Myostatin and Irisin Levels in Postmenopausal Women: Association With Bone Mineral Density and Muscle Strength · not yet recruiting
- NCT07480330 — Serum Neurofilament Light Chain Levels and Neuropathy Severity in Diabetic Polyneuropathy · not yet recruiting
- NCT07425405 — Daily Screen Exposure and Preoperative Anxiety in Children Aged 2-5 Years · recruiting
- NCT07358754 — The Relationship Between Serum S100B and Brain-Derived Neurotrophic Factor · recruiting
- NCT07261436 — Performance Comparison of Large Language Models in TAP Block Ultrasound Interpretation · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03777371 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kanuni Sultan Suleyman Training and Research Hospital
- Last refreshed: 17 December 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03777371.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing